EAM
JAZZ icon

Eagle Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Eagle Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,965
Closed -$2.13M – 564
2024
Q2 		$2.13M Buy
+19,965
New +$2.2M 0.01% 467
2024
Q1 		– Sell
-17,717
Closed -$2.18M – 591
2023
Q4 		$2.18M Buy
+17,717
New +$2.21M 0.01% 447
2021
Q1 		– Sell
-50
Closed -$7K – 638
2020
Q4 		$7K Buy
+50
New +$7.45K ﹤0.01% 563
2016
Q1 		– Sell
-103,981
Closed -$3.49M – 642
2015
Q4 		$3.49M Buy
103,981
+89,169
+602% +$12.4M 0.02% 467
2015
Q3 		$1.97M Buy
14,812
+1,557
+12% +$268K 0.01% 558
2015
Q2 		$2.33M Buy
+13,255
New +$2.38M 0.01% 534

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eagle Asset Management's JAZZ Position: Q3 2024 in Review

Eagle Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 19,965 shares — an estimated $2.13M sold.

Eagle Asset Management first reported a position in JAZZ in Q2 2015 and held it in 6 quarters. The position peaked at $3.49M in Q4 2015. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Eagle Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eagle Asset Management sold 19,965 Jazz Pharmaceuticals shares in Q3 2024, an estimated $2.13M.
  • Eagle Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Eagle Asset Management's Jazz Pharmaceuticals position peaked at $3.49M in Q4 2015.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.